Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Payables (2016 - 2025)

Editas Medicine (EDIT) has disclosed Payables for 11 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • Quarterly Payables fell 74.68% to $3.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Sep 2025, down 74.68% year-over-year, with the annual reading at $5.5 million for FY2024, 33.57% down from the prior year.
  • Payables for Q3 2025 was $3.2 million at Editas Medicine, down from $6.7 million in the prior quarter.
  • The five-year high for Payables was $13.8 million in Q2 2024, with the low at $3.2 million in Q3 2025.
  • Average Payables over 5 years is $7.4 million, with a median of $6.8 million recorded in 2022.
  • The sharpest move saw Payables soared 100.94% in 2022, then plummeted 74.68% in 2025.
  • Over 5 years, Payables stood at $5.0 million in 2021, then skyrocketed by 88.34% to $9.5 million in 2022, then dropped by 13.06% to $8.3 million in 2023, then tumbled by 33.57% to $5.5 million in 2024, then plummeted by 42.42% to $3.2 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $3.2 million, $6.7 million, and $5.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.